• Ensuring patients continue to get the medicines they need
  • Keeping our employees safe
  • Supporting the public health agenda

You can find some information about all this here. And, depending on what information you need, contact us at the numbers and websites below. We’re here to help.

For general inquiries:  1.800.727.6500
 

For our Diabetes Patient Assistance Program, affordability and NovoCare services: 1.844.NOVO4ME (844.668.6463) or visit NovoCare.com
 

For Rare Bleeding Disorder services, please visit NovoSecure.com
 

If you’re a healthcare professional: NovoMedLink is your source for diabetes product samples and support. For growth hormone, please contact your local representative.

"Patients who rely on our medicines every day, our employees who serve them, and the heroes trying to address the outbreak in our backyard demand our singular focus. Now, during these really challenging times, is when we all have to work together to keep our communities, loved ones and those we care about safe and healthy. We take these responsibilities to heart and want people to know what we are doing and how we can help."

- Doug Langa, Executive Vice President, North America Operations and President of Novo Nordisk Inc

People with diabetes facing financial difficulties as a result of the COVID-19 pandemic can access a free 90-day supply of insulin under Novo Nordisk Inc.’s enhanced Patient Assistance Program (PAP). If you’re experiencing job loss, termination of healthcare benefits, or COBRA extension due to the pandemic, you may be eligible.

For more information, visit NovoCare.com.

For up-to-date information and updates about the novel coronavirus (COVID-19), Consumers and healthcare professionals can visit the Centers for Disease Control and Prevention (CDC) and the websites of your state’s health department. Disease-specific resources to help you manage through the pandemic can be found below. If you’re a patient with concerns or questions, please contact your physician or healthcare provider.

This American Association of Clinical Endocrinologists website offers a convenient checklist that contains all of the essential items those with diabetes need to have readily available in the event of an emergency.

Visit AACE "My Diabetes Emergency Plan"

Some information for people with Type 1 and Type 2 diabetes in managing their diabetes during this public health crisis.

Visit American Diabetes Association

The JDRF is providing information in the interest of helping members of the T1D community make informed decisions regarding their health and well-being.

Visit JDRF

Addresses questions and provides resources for people with diabetes during the pandemic.

Visit TCOYD

Some health and wellness information to help the community make information decisions during this public health crisis.

Visit NHF

The HFA COVID-19 page provides information and resources for the community around health and coverage during this public health crisis.

Visit HFA

This page includes medical news and resources, and practical recommendations for people with hemophilia.

Visit Coalition for Hemophilia B

This page includes information and resources for hematologists.

Visit ASH

Based on the science of obesity, facts to help you move forward with weight management during the pandemic.

Visit Truth About Weight

Where health care professionals can learn more about the science of obesity and other topics, including why their role in this complex disease is so important. 

Visit Rethink Obesity

Artists use their voices and platforms to encourage Americans to get the facts on COVID-19 and obesity.  

Visit The Creative Coalition

A website that offers a wealth of relevant information and resources. 

Visit The Obesity Society

The latest on COVID-19 and its impact on people living with obesity and how you too an be an advocate for change.

Vist Obesity Action Coalition

With a special focus on obesity and COVID-19, this intensive report shares recommendations on how to work together to address the challenge of obesity.

Find resources about weight bias and stigma at UCONN Rudd Center and take the Harvard Implicit Bias Test at Project Implicit.

Visit Trust for America's Health

A 2021 report from Xcenda, a leading health economics and outcomes research company, says reducing obesity prevalence could result in fewer deaths from COVID-19, especially in underserved communities, reinforcing one of many reasons effective interventions are needed to treat and reduce obesity. Xcenda’s model shows that a 5% reduction in obesity prevalence at the start of the pandemic could have reduced COVID-19 deaths by 5,000.

During the global coronavirus outbreak, a key priority for Novo Nordisk is to safeguard the continued supply of our lifesaving medicines to patients. At present, we do not foresee a disruption in our ability to supply the U.S. market with our medicines, including insulin, growth hormone or medicines for rare bleeding disorders. We have an inventory policy that helps ensure long-term supply. This is important since our medicines are needed every day by patients all over the world.

We are continuing to provide our family of over 5,000 employees with information, resources and expanded benefits to support them during the COVID-19 pandemic. Importantly, serving patients means that our employees have to be available and healthy to ensure our continued operations, regardless of their locations in offices, laboratories, on production lines or as representatives out in the community calling on customers.  

At our manufacturing facilities, we have implemented procedures to support the health and safety of our essential employees so they can continue production of our medicines 24/7 throughout the pandemic.

We remain committed to doing our part for the communities we serve. We’ve provided more than a million dollars in monetary and in-kind donations to national relief organizations, as well as to New York City/New Jersey/Philadelphia relief efforts, including Direct Relief, AmeriCares, the NYC Emergency COVID-19 Relief Fund, the New Jersey Pandemic Relief Fund and the Philadelphia COVID-19 Relief Fund. Our relief efforts also included:

  • Partnering with more regional and national organizations to help support local families with their basic needs, including the Partnership for Healthier America’s Fresh Food Fund that provided Denver families with 600,000 servings of fresh fruit and vegetables that might have otherwise gone to waste.
  • Donating PPE supplies to local health systems in New Jersey and North Carolina, including for many of our workers at our manufacturing facilities needing this equipment to be able to safely produce medicines. 
  • Supporting employees who are safely volunteering to help those in need in their own communities. Employees are supporting food banks and community food distribution programs, helping thousands of local families in need receive fresh, healthy food.

A: We already have a number of programs to support people who can’t afford their insulin that we believe are quite relevant during COVID-19.  At the same time, we recognize that there are many people who are losing their jobs and or their insurance.  Beginning April 14, 2020, people with diabetes using our insulin who have lost health insurance coverage because of a change in job status due to COVID-19 became eligible for enrollment in our Diabetes Patient Assistance Program (PAP) to receive insulin free-of-charge for 90 days. This program will be available through June 30, 2021. There are eligibility requirements, but we are making the process as quick and easy as possible.

A: If someone is facing a loss of healthcare benefits, Novo Nordisk will not require documented proof of income to qualify. We will require documentation showing loss of healthcare benefits, such as through job termination notice or job status change, or notification that COBRA is being offered. And, in situations where required documentation is not quickly accessible and there is a risk of rationing, we have an Immediate Supply option available that may help by providing what amounts to a free, one-month supply (up to three vials or two packs of pens) for many.  

A: After the first 90-days, ongoing eligibility will be assessed including proof of Medicaid denial for coverage. We will contact the patient every 90 days to ensure no change in coverage/employment. Beyond the COVID-19 crisis, we will continue working with patients facing affordability challenges to identify potential long-term options from our existing affordability offerings.

A: Our criteria and enrollment processes are not changing for Medicare patients. More on those criteria can be found on NovoCare.com

Additionally, starting April 1, 2020, Novo Nordisk removed a requirement that Medicare Part D patients pay $1,000 in out of pocket prescription drug expenses before becoming eligible to participate in the Novo Nordisk Diabetes PAP. This change will expand access for eligible Medicare Part D patients to receive their Novo Nordisk medication at no cost.

A: Medicare recipients are government beneficiaries. CMS requires that once someone using Medicare is enrolled in a patient assistance program, they automatically have to remain in it for the rest of the year. It’s a different situation for someone losing commercial insurance. Medicaid offers support that keeps medicine and overall healthcare costs low during this time.

A: This is being used for lifesaving medicines like insulin. It does not apply to our GLP-1 or growth hormone medicines at this time. However, other affordability options are available for most of those medicines.

A: This program has been extended until June 30, 2021.

A: Complete information about every Novo Nordisk diabetes affordability option can be found on one website - NovoCare.com (or by calling us at 1.844.NOVO4ME) - and many eligible patients can get a solution for medicines they need in minutes. 

A: Our warehouses have a full inventory of medicines, including insulin, to fulfill orders and replenish wholesalers and pharmacies through this pandemic. However, we are seeing an increase in demand and there may be times when someone cannot get their prescription right away because the pharmacy or local wholesaler distribution center is temporarily out of stock of diabetes medicines. We encourage patients to plan ahead and call their pharmacy to see if there are any delays. There is no delay in obtaining growth hormone or medications for rare bleeding disorders.

If you have an affordability challenge or an immediate need, we may be able to help. Please go to NovoCare.com.

If you have a Rare Bleeding Disorder and are looking for support, please visit NovoSecure.com for options that may be appropriate for you.

A: All our active ingredients are manufactured in Denmark. Some of those medicines – Victoza, Norditropin, Ozempic, Rybelsus and our hemophilia medicines – are filled and packaged in Denmark and shipped to the US. Other medicines – our insulins – are filled and packaged here in the US.

A: Only our NovoPen Echo, a durable insulin delivery device, is manufactured in Tianjin, China.

A: As the coronavirus situation worsens in the US, we will work closely with local and regional authorities to ensure our medicines get to the patients who need them. We’re continually monitoring the public health situation and will adjust as necessary.

Our warehouses have a full inventory of medicines, including insulin, to fulfill orders and replenish wholesalers and pharmacies through this pandemic, along with medicines in various production stages at our manufacturing plants. However, we are seeing an increase in demand and there may be times when someone cannot get their prescription right away because the pharmacy or local wholesaler distribution center is temporarily out of stock of diabetes medicines. We encourage patients to plan ahead and call their pharmacy to see if there are any delays. There is no delay in obtaining growth hormone or medicines for rare bleeding disorders.

If you have an affordability challenge or an immediate need, we may be able to help. Please go to NovoCare.com.

If you have a Rare Bleeding Disorder and are looking for support, please visit NovoSecure .com for options that may be appropriate for you.

A: Our US products do not have any active ingredients from China.

A: No. Rationing or reducing the dose of your medication may cause dangerous health consequences for you.  Continue taking your medicine exactly as your Health Care Provider has prescribed it and discuss with them any specific changes in dose or medication type. If you have an affordability challenge or an immediate need, we may be able to help. Please go to NovoCare.com or for rare bleeding disorders, NovoSecure.com.

A: Contact your Healthcare Provider if you wish to increase the amount of medicine you receive per prescription. He or she may also have you contact your health insurance company to understand your options. 

A: Contact your health insurance company about getting your prescriptions delivered to your home. You can also check if your local pharmacy is offering home delivery or has a drive-thru window. 

A: We encourage you to plan ahead. Order your refills as early as your health insurance company will allow—at least two weeks in advance, if possible. You may want to set up a reminder on your phone or calendar for this. While health insurance companies don’t normally pay for refills before they are due, an exception may be made considering coronavirus concerns. You can also check with your local pharmacy if they offer auto-refills.

A: Product samples are provided to Healthcare Providers; please call your current provider and check if he/she has any available to provide you. 

A: Reach out and work more closely with your Healthcare Provider. They know your personal health history best and will be able to work with you on how you can best take care of your disease. If you have questions specific to a Novo Nordisk medicine, please call us at 1.800.727.6500.

A: We encourage you to regularly check in with your loved one and have them contact their Healthcare Provider more regularly during this time.